Medline ® Abstract for Reference 111
of 'Prognostic and predictive factors in early, nonmetastatic breast cancer'
Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections.
Müller BM, Brase JC, Haufe F, Weber KE, Budzies J, Petry C, Prinzler J, Kronenwett R, Dietel M, Denkert C
J Clin Pathol. 2012 Jul;65(7):660-2. Epub 2012 Mar 23.
AIM: This study compared the perfomance of the RNA-based EndoPredict multigene test on core biopsies and surgical breast cancer specimens and analysed the influence of biopsy-induced tissue injuries on the test result.
METHODS: 80 formalin-fixed paraffin-embedded samples comprising paired biopsies and surgical specimens from 40 ER-positive, HER2-negative patients were evaluated. Total RNA was extracted and the EndoPredict score was determined.
RESULTS: RNA yield was considerably lower in core biopsies, but sufficient to measure the assay in all samples. The EndoPredict score was highly correlated between paired samples (Pearson r=0.92), with an excellent concordance of classification into a low or high risk of metastasis (overall agreement 95%).
CONCLUSIONS: The measurements are comparable between core biopsies and surgical sections, which suggest that the EndoPredict assay can be performed on core biopsy tissue. Inflammatory changes induced by presurgical biopsies had no significant effect on the RNA-based risk assessment in surgical specimens.
Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany. firstname.lastname@example.org